Intravenous immunoglobulin treatment abrogates transplacental autoantibody transfer in a murine pemphigus model - 06/06/18
Doi : 10.1016/j.jaci.2017.12.985
Sachiko Ono, MD, PhD a, Gyohei Egawa, MD, PhD a 
, Tetsuya Honda, MD, PhD a, Kenji Kabashima, MD, PhD a, b
, Tetsuya Honda, MD, PhD a, Kenji Kabashima, MD, PhD a, b a Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
b Singapore Immunology Network (SIgN) and Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore
| This work was supported by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (grant nos. 263395, 15H05790, 15H1155, and 15K15417), Japan Science and Technology Agency, Precursory Research for Embryonic Science and Technology (PRESTO) (grant no. 16021031300), and Japan Agency for Medical Research and Development (AMED) (grant nos. 16ek0410011h0003 and 16he0902003h0002). |
|
| Disclosure of potential conflict of interest: G. Egawa reports grants/grants pending from GlaksoSmithKline, Japan, and Novartis Pharma. T. Honda reports pending grants/grants from Mitsubishi Tanabe Pharma, Sanofi Japan Group, AbbVie GK, Lydia O'leary Memorial Pias Dermatological Foundation, ROHTO Pharmaceutical Co, Shiseido Co, Novartis International AG, and Kao Co; and payment for lectures including service on speakers bureaus from Novartis International AG, AbbVie GK, Sanofi Japan Group, Mitsubishi Tanabe Pharma, Janssen Pharma, Kyowa Hakko Kirin, and Torii Pharmaceutical, Co, Ltd. K. Kabashima reports grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT), and Japan Society for the Promotion of Science; payment for writing or reviewing the manuscript from Sanofi Japan Group; grants/grants pending from Sanofi Japan Group, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical Co, Ltd, Pola Pharma, and Maruho; and payment for lectures including service on speakers bureaus from Pola Pharma, Kyowa Hakko Kirin, Maruho, and Leo Pharma. S. Ono declares no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 6
P. 2273 - juin 2018 Retour au numéro
Article précédent
- Airway inflammation after epicutaneous sensitization of mice requires protease activity of low-dose allergen inhalation
- Izumi Nishioka, Toshiro Takai, Natsuko Maruyama, Seiji Kamijo, Punyada Suchiva, Mayu Suzuki, Shinya Kunimine, Hirono Ochi, Sakiko Shimura, Katsuko Sudo, Hideoki Ogawa, Ko Okumura, Shigaku Ikeda
- Human dendritic cell subset 4 (DC4) correlates to a subset of CD14dim/?CD16++ monocytes
- Federica Calzetti, Nicola Tamassia, Alessandra Micheletti, Giulia Finotti, Francisco Bianchetto-Aguilera, Marco A. Cassatella
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?